CHELSEA CHAMBERS: Open Payments
NPI 1194507855 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,184 in 94 payments from 20 companies in 2025. Trend: 2023 $246 · 2024 $3,521 · 2025 $2,184
Food & beverage: $2,184
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $433 |
| ABBVIE INC. | 18 | $344 |
| Novo Nordisk Inc | 12 | $287 |
| PFIZER INC. | 15 | $265 |
| Amgen Inc. | 10 | $178 |
| Corcept Therapeutics | 1 | $109 |
| Lilly USA, LLC | 5 | $86 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $85 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $81 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $50 |
Products named: BREZTRI, Ozempic, VRAYLAR, OTEZLA, NURTEC ODT, ELIQUIS, AIRSUPRA, Korlym.
Industry payments across NV — which companies pay providers there.
